Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prestige Consumer Healthcare (PBH) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to $2.4 million.

  • Prestige Consumer Healthcare's Change in Accured Expenses fell 3549.67% to $2.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.0 million, marking a year-over-year increase of 31771.69%. This contributed to the annual value of $7.0 million for FY2025, which is 14306.59% up from last year.
  • According to the latest figures from Q4 2025, Prestige Consumer Healthcare's Change in Accured Expenses is $2.4 million, which was down 3549.67% from $4.7 million recorded in Q3 2025.
  • In the past 5 years, Prestige Consumer Healthcare's Change in Accured Expenses ranged from a high of $18.4 million in Q2 2021 and a low of -$23.1 million during Q1 2021
  • Its 5-year average for Change in Accured Expenses is -$283250.0, with a median of $830500.0 in 2022.
  • In the last 5 years, Prestige Consumer Healthcare's Change in Accured Expenses soared by 37941.79% in 2023 and then plummeted by 45398.41% in 2024.
  • Over the past 5 years, Prestige Consumer Healthcare's Change in Accured Expenses (Quarter) stood at -$9.5 million in 2021, then skyrocketed by 84.84% to -$1.4 million in 2022, then soared by 379.42% to $4.0 million in 2023, then dropped by 6.37% to $3.8 million in 2024, then crashed by 35.5% to $2.4 million in 2025.
  • Its Change in Accured Expenses was $2.4 million in Q4 2025, compared to $4.7 million in Q3 2025 and -$813000.0 in Q2 2025.